Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Millennium Management LLC increased its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 11.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 115,642 shares of the biotechnology company’s stock after buying an additional 12,285 shares during the period. Millennium Management LLC owned 0.25% of Capricor Therapeutics worth $1,596,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CAPR. Summit Investment Advisors Inc. raised its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $68,000. AlphaQuest LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $78,000. Finally, New York State Common Retirement Fund raised its position in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on CAPR shares. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Roth Capital initiated coverage on shares of Capricor Therapeutics in a research report on Tuesday, May 20th. They issued a “buy” rating and a $31.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and an average price target of $35.50.

Capricor Therapeutics Trading Up 9.2%

NASDAQ CAPR opened at $11.15 on Wednesday. The firm has a market capitalization of $509.30 million, a price-to-earnings ratio of -10.52 and a beta of 0.85. The firm’s 50 day simple moving average is $10.14 and its 200 day simple moving average is $13.03. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The company had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter in the prior year, the business earned ($0.31) EPS. On average, equities research analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.